Medigen Biotechnology Past Earnings Performance
Past criteria checks 0/6
Medigen Biotechnology's earnings have been declining at an average annual rate of -10%, while the Biotechs industry saw earnings growing at 21.4% annually. Revenues have been growing at an average rate of 11.8% per year.
Key information
-10.0%
Earnings growth rate
-9.9%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 11.8% |
| Return on equity | -17.5% |
| Net Margin | -29.2% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How Medigen Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,413 | -413 | 596 | 926 |
| 30 Jun 24 | 1,393 | -433 | 585 | 1,014 |
| 31 Mar 24 | 1,245 | -542 | 530 | 1,278 |
| 31 Dec 23 | 1,158 | -561 | 514 | 1,336 |
| 30 Sep 23 | 990 | -594 | 476 | 1,017 |
| 30 Jun 23 | 749 | -663 | 436 | 1,227 |
| 31 Mar 23 | 735 | -689 | 434 | 1,186 |
| 31 Dec 22 | 1,056 | -676 | 423 | 1,331 |
| 30 Sep 22 | 3,029 | -244 | 406 | 1,443 |
| 30 Jun 22 | 4,238 | -64 | 411 | 1,299 |
| 31 Mar 22 | 4,221 | -70 | 402 | 1,459 |
| 31 Dec 21 | 3,922 | -53 | 365 | 1,407 |
| 30 Sep 21 | 1,936 | -196 | 354 | 1,295 |
| 30 Jun 21 | 705 | -371 | 340 | 1,289 |
| 31 Mar 21 | 670 | -332 | 325 | 1,012 |
| 31 Dec 20 | 616 | -338 | 338 | 836 |
| 30 Sep 20 | 595 | -412 | 340 | 775 |
| 30 Jun 20 | 551 | -388 | 320 | 690 |
| 31 Mar 20 | 577 | -396 | 323 | 681 |
| 31 Dec 19 | 552 | -394 | 320 | 698 |
| 30 Sep 19 | 473 | -444 | 287 | 679 |
| 30 Jun 19 | 461 | -444 | 286 | 659 |
| 31 Mar 19 | 404 | -429 | 290 | 619 |
| 31 Dec 18 | 407 | -396 | 296 | 586 |
| 30 Sep 18 | 423 | -309 | 275 | 515 |
| 30 Jun 18 | 430 | -315 | 287 | 514 |
| 31 Mar 18 | 436 | -323 | 293 | 481 |
| 31 Dec 17 | 427 | -393 | 301 | 484 |
| 30 Sep 17 | 415 | -417 | 358 | 495 |
| 30 Jun 17 | 408 | -474 | 368 | 476 |
| 31 Mar 17 | 397 | -560 | 385 | 467 |
| 31 Dec 16 | 400 | -568 | 386 | 471 |
| 30 Sep 16 | 405 | -597 | 352 | 489 |
| 30 Jun 16 | 401 | -575 | 334 | 513 |
| 31 Mar 16 | 392 | -512 | 302 | 532 |
| 31 Dec 15 | 363 | -541 | 286 | 557 |
| 30 Sep 15 | 364 | -543 | 274 | 574 |
| 30 Jun 15 | 364 | -731 | 261 | 589 |
| 31 Mar 15 | 361 | -742 | 242 | 633 |
| 31 Dec 14 | 372 | -702 | 225 | 614 |
| 30 Sep 14 | 285 | -679 | 209 | 605 |
| 30 Jun 14 | 211 | -469 | 168 | 627 |
| 31 Mar 14 | 134 | -431 | 145 | 576 |
| 31 Dec 13 | 73 | -364 | 112 | 519 |
Quality Earnings: 3176 is currently unprofitable.
Growing Profit Margin: 3176 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 3176 is unprofitable, and losses have increased over the past 5 years at a rate of 10% per year.
Accelerating Growth: Unable to compare 3176's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 3176 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.8%).
Return on Equity
High ROE: 3176 has a negative Return on Equity (-17.5%), as it is currently unprofitable.